Portal de Periódicos da CAPES

Immunotherapy in Older Adults With Cancer

2021; Lippincott Williams & Wilkins; Volume: 39; Issue: 19 Linguagem: Inglês

10.1200/jco.21.00138

1527-7755

Carolyn J. Presley, Fábio Gomes, Christin E. Burd, Ravindran Kanesvaran, Melisa L. Wong,

Frailty in Older Adults

Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00138 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043444 Immunotherapy in Older Adults With Cancer Carolyn J. Presley , MD, MHS1xCarolyn J. PresleySearch for articles by this author; Fabio Gomes , MD2xFabio GomesSearch for articles by this author; Christin E. Burd , MD3xChristin E. BurdSearch for articles by this author; Ravindran Kanesvaran , MD4xRavindran KanesvaranSearch for articles by this author; and Melisa L. Wong , MD, MAS5xMelisa L. WongSearch for articles by this author Show More 1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH2Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK3Departments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH4Division of Medical Oncology, National Cancer Centre Singapore, Singapore5Divisions of Hematology/Oncology and Geriatrics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA https://doi.org/10.1200/JCO.21.00138 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveWhat is known about immune checkpoint inhibitor (ICI) clinical efficacy and toxicity among older adults with cancer, and how does toxicity management differ in this vulnerable population?Knowledge GeneratedAmong fit older adults included in clinical trials, ICI efficacy and toxicity are comparable with younger adults, although efforts to study ICI use among frail older adults cared for in everyday practice are ongoing. Toxicity management among older adults must consider comorbidities and ideally include primary care teams and caregivers.RelevanceThe data reviewed here can help clinicians assess the benefits and harms of immunotherapy using an individualized approach aimed at improving goal-concordant care and patient outcomes among older adults with cancer.SUPPORTC.J.P. is supported by the National Institute on Aging (R03AG064374) and the Ohio State University Comprehensive Cancer Center. C.E.B. is supported by the National Institute on Aging (R01AG059711). M.L.W. is supported by the National Institute on Aging (R03AG056439, K76AG064431) and the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. The Cancer and Aging Research Group also supported this review (R33AG059206).AUTHOR CONTRIBUTIONSConception and design: Carolyn J. Presley, Melisa L. WongCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTImmunotherapy in Older Adults With CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Carolyn J. PresleyConsulting or Advisory Role: PotentiaMetrics, Onc LiveFabio GomesHonoraria: AstraZenecaChristin E. BurdStock and Other Ownership Interests: Abbvie, Luminex, GE Healthcare, Gilead SciencesRavindran KanesvaranHonoraria: Astellas Pharma, Novartis, Janssen, MSD Oncology, Bristol-Myers SquibbConsulting or Advisory Role: Pfizer, Astellas Pharma, Novartis, MSD Oncology, Janssen OncologyResearch Funding: Sanofi, JanssenTravel, Accommodations, Expenses: Astellas Pharma, MSD Oncology, Bristol-Myers SquibbMelisa L. WongEmployment: Roche/GenentechStock and Other Ownership Interests: Roche/GenentechNo other potential conflicts of interest were reported.